20 May 2016 - Pfizer today announced the EMA has accepted the Marketing Authorization Application for Trumenba (Meningococcal Group B Vaccine) for review.

Trumenba has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older.

The acceptance marks the beginning of the regulatory review process for this vaccine in the EU.

For more details, go to: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_european_medicines_agency_acceptance_for_review_of_marketing_authorization_application_for_trumenba_meningococcal_group_b_vaccine